HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

430.463

+8.7162.07%

Number of Gainers:27

Number of Losers:4

Number of Flat:3

PE:- -

High:431.911

Open:421.747

Low:421.747

Close:421.747

Loading ...

Everest Medicines Announces First Patient Dosed With Evm16, Its First Internally Developed Personalized Mrna Cancer Vaccine

THOMSON REUTERS

Everest Medicines Ltd - Evm16 Shows Synergistic Effect With Pd-1 Antibody in Preclinical Data

THOMSON REUTERS

Everest Medicines Ltd - Evm16 Well Tolerated and Safe in Preclinical Toxicity Studies

THOMSON REUTERS

CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug

MT Newswires Live

HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody

MT Newswires Live

China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy

MT Newswires Live

Peijia Medical Completes First Two Implants with Transcatheter System; Shares Up 8%

MT Newswires Live

BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal

BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation

BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG

Akeso Announces Completion of Patient Enrollment in the Phase Iii Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

THOMSON REUTERS

CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl

THOMSON REUTERS

Hbm Holdings - Upfront Payment Received Under License Agreement With Windward Bio Ag for Hbm9378/Skb378

THOMSON REUTERS

Ascentage Pharma Group International - Olverembatinib Given Breakthrough Therapy Designation by Center for Drug Evaluation of China Nmpa

THOMSON REUTERS

BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Olverembatinib Granted Breakthrough Therapy Designation for Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":430.4633,"timestamp":1741248510375,"preClose":421.74713,"halted":0,"volume":196751826,"delay":0,"changeRate":0.020667,"change":8.716156,"pbRate":3.352817,"amount":2078205803,"amplitude":0.024099,"prevYearClose":331.1933,"fiveDayClose":431.446,"twentyDayClose":333.662,"turnoverRate":0.00762,"marketCap":241153069920,"floatMarketCap":226975358368,"peRate":-16.712341},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":431.91098,"amplitude":0.024099,"preClose":421.74713,"low":421.74713,"pbRate":"3.352817","latestPrice":430.4633,"volume":196751826,"delay":0,"open":421.74713,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":431.446,"twentyDayClose":333.662,"sixtyDayClose":346.493,"secType":"PLATE","market":"HK","turnoverRate":0.00762,"peRate":-16.712341,"marketCap":241153069920,"floatMarketCap":226975358368,"timestamp":1741248510375,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":27,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517813874","title":"Everest Medicines Announces First Patient Dosed With Evm16, Its First Internally Developed Personalized Mrna Cancer Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2517813874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517813874?lang=en_us&edition=fundamental","pubTime":"2025-03-06 16:30","pubTimestamp":1741249803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA99ZLJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2517613870","title":"Everest Medicines Ltd - Evm16 Shows Synergistic Effect With Pd-1 Antibody in Preclinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2517613870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517613870?lang=en_us&edition=fundamental","pubTime":"2025-03-06 16:30","pubTimestamp":1741249803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA99ZLJF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","01952","BK1574","BK1161"],"gpt_icon":0},{"id":"2517138709","title":"Everest Medicines Ltd - Evm16 Well Tolerated and Safe in Preclinical Toxicity Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2517138709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517138709?lang=en_us&edition=fundamental","pubTime":"2025-03-06 16:30","pubTimestamp":1741249803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA99ZLJF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2517185242","title":"CStone Pharmaceuticals Submit Clinical Trial Application in Australia for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185242?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:46","pubTimestamp":1741243589,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  submitted the Phase I-B trial application in Australia for its large B-cell lymphoma  drug, according to a Thursday filing with the Hong Kong bourse.CS5001 is an ROR1-targeting antibody-drug conjugate  that works with first-line standard-of-care  to diffuse large B-cell lymphoma , the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02616","XJO.AU","BK1161","ADC","BK4080","BK4231","XAO.AU","XKO.AU","BK1574","BK7095","ADC.AU"],"gpt_icon":0},{"id":"2517185660","title":"HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185660?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:40","pubTimestamp":1741243252,"startTime":"0","endTime":"0","summary":"HBM Holdings  received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.The company and Sichuan Kelun-Biotech Biopharmaceutical  had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06990","BK1583","BK1161","LU0196878994.USD","02142"],"gpt_icon":0},{"id":"2517183402","title":"China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517183402","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517183402?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:29","pubTimestamp":1741242590,"startTime":"0","endTime":"0","summary":"The Center for Drug Evaluation of China's National Medical Products Administration granted Ascentage Pharma Group International's  olverembatinib its third breakthrough therapy designation, a Thursday bourse filing said.The designation is for the drug's combination with low-intensity chemotherapy for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of blood cancer caused by a genetic mutation in certain chromosomes.The drug has been granted breakthrough therapy designation twice before, once in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia and then in June 2023 for patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2517002889","title":"Peijia Medical Completes First Two Implants with Transcatheter System; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517002889","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517002889?lang=en_us&edition=fundamental","pubTime":"2025-03-06 13:50","pubTimestamp":1741240218,"startTime":"0","endTime":"0","summary":"Peijia Medical  has completed the first two implants with the TrilogyTM Transcatheter Heart Valve System to treat severe aortic regurgitation in Taiwan, China, a Wednesday filing with the Hong Kong bourse said.The system is indicated for use in patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.Shares of the company were up over 8% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09996","BK1574","BK1100","BK1583"],"gpt_icon":0},{"id":"2517901950","title":"BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2517901950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517901950?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:08","pubTimestamp":1741234095,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal** Shares of Chinese immunology diseases therapeutics developer Hbm Holdings Ltd 2142.HK rise 4.8% to HK$6.27, their highest since January 2022, and on course for second session of gains** Hbm says co, as a licensor in a license agreement for product HBM9378/SKB378, has received an upfront payment from licensee Windward Bio AG, which will bolster co's cash reserves** It gives no further details** Hong Kong's healthcare index .HSCIH climbs 1.1%, Hang Seng Index .HSI rises 2.5%** Stock up 221.5% YTD    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL2N3PP04E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1583","02142"],"gpt_icon":0},{"id":"2517716729","title":"BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517716729","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517716729?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:52","pubTimestamp":1741222374,"startTime":"0","endTime":"0","summary":"BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation March 6 (Reuters) - Ascentage Pharma Group International 6855.HK:OLVEREMBATINIB GIVEN BREAKTHROUGH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2517971674","title":"BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971674","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971674?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:52","pubTimestamp":1741222350,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG March 6 (Reuters) - Hbm Holdings Ltd 2142.HK:UPFRONT PAYMENT RECEIVED UNDER LICENSE AGREEMENT WITH WINDWARD BIO AG FOR HBM9378/SKB378Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2517979311","title":"Akeso Announces Completion of Patient Enrollment in the Phase Iii Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517979311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517979311?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:30","pubTimestamp":1741221002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA48VPCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1794554557.SGD","IE00BPRC5H50.USD","BK1574","IE00B5MMRT66.SGD","09926","LU0348783233.USD","LU0417516571.SGD","BK1161","IE00B543WZ88.USD","LU2488822045.USD","LU1720050803.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2517976361","title":"CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976361?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:10","pubTimestamp":1741219803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA2T0MDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2517975240","title":"Hbm Holdings - Upfront Payment Received Under License Agreement With Windward Bio Ag for Hbm9378/Skb378","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975240?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:00","pubTimestamp":1741219250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","02142"],"gpt_icon":0},{"id":"2517975834","title":"Ascentage Pharma Group International - Olverembatinib Given Breakthrough Therapy Designation by Center for Drug Evaluation of China Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975834?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:43","pubTimestamp":1741218211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO0WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2517978453","title":"BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978453","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978453?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:03","pubTimestamp":1741215813,"startTime":"0","endTime":"0","summary":"BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)March 5 (Reuters) - Ascentage Pharma Group I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"2517978965","title":"Olverembatinib Granted Breakthrough Therapy Designation for Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978965?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:01","pubTimestamp":1741215701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":62}]}}